Perrigo Company plc vs Wave Life Sciences Ltd.: Strategic Focus on R&D Spending

R&D Spending: Perrigo vs. Wave Life Sciences

__timestampPerrigo Company plcWave Life Sciences Ltd.
Wednesday, January 1, 20141525000002395000
Thursday, January 1, 20151878000009057000
Friday, January 1, 201618400000040818000
Sunday, January 1, 201716770000079309000
Monday, January 1, 2018218600000134428000
Tuesday, January 1, 2019187400000175431000
Wednesday, January 1, 2020177700000130944000
Friday, January 1, 2021122000000121875000
Saturday, January 1, 2022123100000115856000
Sunday, January 1, 2023122500000130009000
Loading chart...

Unlocking the unknown

Strategic R&D Investments: A Tale of Two Companies

In the competitive landscape of pharmaceuticals and biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Perrigo Company plc and Wave Life Sciences Ltd. have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, Perrigo's R&D expenses have shown a steady decline, dropping by approximately 20% from their peak in 2018. In contrast, Wave Life Sciences has aggressively increased its R&D spending, with a staggering 54-fold increase from 2014 to 2019, reflecting its strategic focus on pioneering new therapies. By 2023, Wave Life Sciences' R&D expenses nearly matched those of Perrigo, highlighting its rapid ascent in the industry. This data underscores the dynamic nature of R&D strategies and their potential impact on a company's market position.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025